Analytical Data
-
Gene name
Siglec-9
-
简介
Siglec-9 Protein, a putative adhesion molecule, mediates sialic-acid dependent cellular binding with a preference for alpha-2,3- or alpha-2,6-linked sialic acid. Its sialic acid recognition site may undergo masking through cis interactions with sialic acids on the same cell surface. Siglec-9 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Siglec-9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
Alternative Names
CD329; CDw329; FOAP-9; OBBP-Like; Siglec-9; SIGLEC9
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y336-1
-
Expression Region
Q18-G348
-
Protein Length
Extracellular Domain
-
Molecular Weight
70-80 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-9, or sialic acid-binding immunoglobulin-like lectin 9, is a member of the Siglec family of receptors that play critical roles in regulating immune response, particularly in the context of inflammation and autoimmunity. Research interest in Siglec-9 has surged due to its unique ability to bind sialic acid residues, which are often found on the surface of cells and pathogens. This binding mediates various immune responses, including the inhibition of pro-inflammatory signaling pathways, which can be particularly beneficial in managing chronic inflammatory conditions or in the context of cancer immunotherapy. Moreover, studies have indicated that Siglec-9 is preferentially expressed on myeloid cells, such as macrophages and dendritic cells, suggesting its involvement in modulating immune cell interactions and influencing the adaptive immune response. The recombinant expression of Siglec-9 has enabled researchers to create tools for investigating its functional properties and potential therapeutic applications. Understanding the mechanisms by which Siglec-9 regulates immune responses could pave the way for novel treatments for autoimmune diseases, enhance vaccine efficacy, and improve strategies for cancer immunotherapy. As such, the exploration of Siglec-9 as a therapeutic target is a promising area in immunology, drawing interest from both basic and clinical research fields.
